I agree that this site is using cookies. You can find further informations here.
X
Agustoni, F.
1531  results:
Search for persons X
?
1

125P Preliminary analysis on safety of the DEDALUS phase II..:

Filippi, A.R. ; Saddi, J. ; Agustoni, F....
ESMO Open.  9 (2024)  - p. 102704 , 2024
Link: https://doi.org/10.1016/..
 
?
2

OC.04.7: A ONE-YEAR FOLLOW-UP STUDY ON CHECKPOINT INHIBITOR..:

Lenti, M.V. ; Broglio, G. ; Ribaldone, D.G....
Digestive and Liver Disease.  56 (2024)  - p. S144-S145 , 2024
Link: https://doi.org/10.1016/..
 
?
3

PO-2100 Radiomic features and PFS post-PACIFIC in the Blue ..:

Filippi, A.R. ; Saddi, J. ; Ballante, E....
Radiotherapy and Oncology.  182 (2023)  - p. S1883-S1884 , 2023
Link: https://doi.org/10.1016/..
 
?
4

PD-0962 Second PFS after post-PACIFIC relapse in the Blue S..:

Filippi, A.R. ; Saddi, J. ; Agustoni, F....
Radiotherapy and Oncology.  182 (2023)  - p. S811 , 2023
Link: https://doi.org/10.1016/..
 
?
5

123P Second progression-free survival (PFS2) after first pr..:

Filippi, A.R.R. ; Saddi, J. ; Agustoni, F....
Journal of Thoracic Oncology.  18 (2023)  4 - p. S110 , 2023
Link: https://doi.org/10.1016/..
 
?
6

Analysis of the humoral and cellular immune response after ..:

Lasagna, A. ; Lilleri, D. ; Agustoni, F....
ESMO Open.  7 (2022)  1 - p. 100359 , 2022
Link: https://doi.org/10.1016/..
 
?
7

198TiP DEDALUS trial: A single-arm, phase II, multi-center ..:

Saddi, J. ; Agustoni, F. ; Arcangeli, S....
Immuno-Oncology and Technology.  16 (2022)  - p. 100310 , 2022
Link: https://doi.org/10.1016/..
 
?
8

A snapshot of the immunogenicity, efficacy and safety of a ..:

Lasagna, A. ; Agustoni, F. ; Percivalle, E....
ESMO Open.  6 (2021)  5 - p. 100272 , 2021
Link: https://doi.org/10.1016/..
 
?
9

7149 POSTER Sequential Use of Targeted Therapies (TT) in Me..:

Verzoni, E. ; Buzzoni, R. ; Agustoni, F....
European Journal of Cancer.  47 (2011)  - p. S520 , 2011
Link: https://doi.org/10.1016/..
 
?
10

Immune checkpoint inhibitors and Carbon iON radiotherapy In..:

Cavalieri S ; Vitolo V ; Barcellini A...
info:eu-repo/semantics/altIdentifier/pmid/36974574.  , 2023
Link: https://hdl.handle.net/2..
 
?
11

Bridging therapeutic opportunities: a survey by the Italian..:

Ciliberto G ; Canfora M ; Terrenato I...
info:eu-repo/semantics/altIdentifier/pmid/36245005.  , 2022
Link: https://hdl.handle.net/2..
 
?
12

EGFR High Copy Number Together with High EGFR Protein Expre..:

Hirsch, F. R ; Redman, M. W ; Moon, J...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8766941/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
13

A Definitive Prognostication System for Patients With Thora..:

Whisenant, J.G ; Baena, J ; Cortellini, A...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jtho.2021.12.015.  , 2022
Link: https://serval.unil.ch/n..
 
?
14

A definitive prognostication system for patients with thora..:

Whisenant, JG ; Baena, J ; Cortellini, A...
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2022.  , 2022
Link: https://repository.icr.a..
 
?
15

Baseline characteristics and outcomes of cancer patients in..:

Di Cosimo S ; Tagliaferri B ; Generali D...
info:eu-repo/semantics/altIdentifier/pmid/33809465.  , 2021
Link: http://hdl.handle.net/23..
 
1-15